CTOs on the Move

HumanTouch

www.humantouch.com

 
Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Les Buday
Director of Cybersecurity Profile

Similar Companies

LTC Group

LTC Group is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diteba Research Laboratories

Diteba Research Laboratories is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lake Shore Inn Nursing Home

Lake Shore Inn Nursing Home is a Waseca, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valley Mental Health

Valley Mental Health is a private, not-for-profit agency, contracting with Salt Lake, Summit and Tooele Counties, as well as with the State of Utah to provide mental health services. Valley Mental Health's philosophy is to deliver services in the least

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.